Kitov Pharmaceuticals to Present at Biotech Showcase in San Francisco on

Pharmaceuticals to Present at Biotech Showcase in San Francisco on January 11, 2016

Israel, January 11, 2016 /PRNewswire/

-- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that Dr. J. Paul

Waymack, Kitov's Chairman of the Board and Chief Medical Officer will

present at the 8th Annual Biotech Showcase in San Francisco at 5:00pm (Pacific Standard

Time) on January 11, 2016. The conference will take place from January 11-13 at the Parc 55 San Francisco.

Registered attendees interested in a one-on-one meeting with management may contact the conference or Kitov directly.

Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies

with an opportunity to present to, and meet with, investors and potential strategics in one place during the course of one of

the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world

gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Kitov Pharmaceuticals Holdings Ltd.

Pharmaceuticals Holdings Ltd. is a pharmaceutical company focused on the development of therapeutic candidates for the simultaneous

treatment of various clinical conditions. In particular, Kitov focuses on developing combinations of existing drugs in advanced

stages of development. Kitov's lead drug, KIT-302, is formulated for the simultaneous treatment of two clinical conditions -

pain caused by osteoarthritis (OA) and hypertension (high blood pressure), which can be pre-existing or caused by the treatment

for OA. KIT-302 is based on celecoxib, the active ingredient of a known and approved-for-use drug designed primarily to relieve

pain caused by OA, and the generic drug amlodipine besylate. Kitov is traded on the Nasdaq Capital Market (KTOV) and the Tel-Aviv

Stock Exchange (KTOV).

release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements

can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations of

these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These

forward-looking statements involve certain risks and uncertainties, including, among others, risks impacting the ability of the

Company to complete any public offering of its securities because of general market conditions or other factors and risks that

could cause the Company's results to differ materially from those expected by Company management. Any forward-looking statement

in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update

or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may

be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company

is contained under the heading "Risk Factors" in Kitov Pharmaceuticals Holdings Ltd.'s Registration Statement on Form

F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov.